DE3918082A1 - Mittel gegen autoimmunerkrankungen - Google Patents

Mittel gegen autoimmunerkrankungen

Info

Publication number
DE3918082A1
DE3918082A1 DE3918082A DE3918082A DE3918082A1 DE 3918082 A1 DE3918082 A1 DE 3918082A1 DE 3918082 A DE3918082 A DE 3918082A DE 3918082 A DE3918082 A DE 3918082A DE 3918082 A1 DE3918082 A1 DE 3918082A1
Authority
DE
Germany
Prior art keywords
cells
alkyl
carbon atoms
lymphocytes
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE3918082A
Other languages
German (de)
English (en)
Other versions
DE3918082C2 (OSRAM
Inventor
Manuel Dipl Chem Dr Modolell
Gerhard Prof Dr Med Munder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to DE3918082A priority Critical patent/DE3918082A1/de
Priority to GR900100406A priority patent/GR1001195B/el
Priority to US07/777,248 priority patent/US5266564A/en
Priority to DE90908504T priority patent/DE59002863D1/de
Priority to DK90908504.5T priority patent/DK0474712T3/da
Priority to AT90908504T priority patent/ATE94757T1/de
Priority to JP2507957A priority patent/JP2977894B2/ja
Priority to CS902689A priority patent/CS276439B6/cs
Priority to ES90908504T priority patent/ES2060173T3/es
Priority to CA002056421A priority patent/CA2056421C/en
Priority to AU56706/90A priority patent/AU5670690A/en
Priority to EP90908504A priority patent/EP0474712B1/de
Priority to PCT/EP1990/000870 priority patent/WO1990014829A1/de
Priority to ZA904196A priority patent/ZA904196B/xx
Priority to IE198790A priority patent/IE64039B1/en
Publication of DE3918082A1 publication Critical patent/DE3918082A1/de
Application granted granted Critical
Publication of DE3918082C2 publication Critical patent/DE3918082C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE3918082A 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen Granted DE3918082A1 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE3918082A DE3918082A1 (de) 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen
GR900100406A GR1001195B (el) 1989-06-02 1990-05-29 Διαδικασια για την παρασκευη μιας φαρμακευτικης συνθεσης για τηνθεραπεια αυτοανοσων νοσηματων.
EP90908504A EP0474712B1 (de) 1989-06-02 1990-05-31 Lysolecithinderivate zur behandlung von autoimmunerkrankungen
DK90908504.5T DK0474712T3 (da) 1989-06-02 1990-05-31 Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat
AT90908504T ATE94757T1 (de) 1989-06-02 1990-05-31 Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
JP2507957A JP2977894B2 (ja) 1989-06-02 1990-05-31 自己免疫疾患用剤
CS902689A CS276439B6 (en) 1989-06-02 1990-05-31 Pharmaceutical for treating auto-immune diseases
ES90908504T ES2060173T3 (es) 1989-06-02 1990-05-31 Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
US07/777,248 US5266564A (en) 1989-06-02 1990-05-31 Method for treating certain autoimmune diseases
AU56706/90A AU5670690A (en) 1989-06-02 1990-05-31 Lysolecithin derivatives for treating autoimmune diseases
DE90908504T DE59002863D1 (de) 1989-06-02 1990-05-31 Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
PCT/EP1990/000870 WO1990014829A1 (de) 1989-06-02 1990-05-31 Lysolecithinderivate zur behandlung von autoimmunerkrankungen
CA002056421A CA2056421C (en) 1989-06-02 1990-05-31 Agent against autoimmune diseases
ZA904196A ZA904196B (en) 1989-06-02 1990-06-01 Process for the preparation of a pharmaceutical composition for the treatment of autoimmune diseases
IE198790A IE64039B1 (en) 1989-06-02 1990-06-01 Derivatives of lysolecithin for the treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3918082A DE3918082A1 (de) 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen

Publications (2)

Publication Number Publication Date
DE3918082A1 true DE3918082A1 (de) 1991-01-24
DE3918082C2 DE3918082C2 (OSRAM) 1992-02-06

Family

ID=6381972

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3918082A Granted DE3918082A1 (de) 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen
DE90908504T Expired - Fee Related DE59002863D1 (de) 1989-06-02 1990-05-31 Lysolecithinderivate zur behandlung von autoimmunerkrankungen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE90908504T Expired - Fee Related DE59002863D1 (de) 1989-06-02 1990-05-31 Lysolecithinderivate zur behandlung von autoimmunerkrankungen.

Country Status (14)

Country Link
US (1) US5266564A (OSRAM)
EP (1) EP0474712B1 (OSRAM)
JP (1) JP2977894B2 (OSRAM)
AT (1) ATE94757T1 (OSRAM)
AU (1) AU5670690A (OSRAM)
CA (1) CA2056421C (OSRAM)
CS (1) CS276439B6 (OSRAM)
DE (2) DE3918082A1 (OSRAM)
DK (1) DK0474712T3 (OSRAM)
ES (1) ES2060173T3 (OSRAM)
GR (1) GR1001195B (OSRAM)
IE (1) IE64039B1 (OSRAM)
WO (1) WO1990014829A1 (OSRAM)
ZA (1) ZA904196B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3941009A1 (de) * 1989-12-12 1991-06-13 Medmark Pharma Gmbh Eliminierung von aktivierten lymphozyten
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
CA2356736A1 (en) * 1998-12-21 2000-06-29 Inkeysa. S.A. Use of etherlysophospholipids as antiinflammatory agents
SE9902155L (sv) * 1999-06-09 2000-12-10 Bjoern Rydevik Serum antibodies
JP2002228764A (ja) * 2001-02-02 2002-08-14 Fuji Photo Film Co Ltd 透光性シート体検出装置
CN101610758A (zh) * 2006-11-10 2009-12-23 阿尔法普托斯有限公司 含有三取代甘油化合物的口服剂型
US8324188B2 (en) 2006-11-10 2012-12-04 Vladimir Khazak Combinations of ET-18-O-CH3and anti-cancer agents for the treatment of cancer
ES2391659T3 (es) * 2006-11-10 2012-11-28 Radioprotect Alphaptose Ug(Haftungsbeschränkt) & Co. Kg Uso de compuestos de glicerol trisustituido para el tratamiento de lesiones por radiación
EP2120873B1 (en) * 2006-12-20 2012-06-27 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
AU2008231570C1 (en) 2007-03-28 2014-11-27 Aker Biomarine Human Ingredients As Bioeffective krill oil compositions
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
CN101827529B (zh) * 2007-08-29 2014-01-15 阿克海洋生物股份公司 制备磷虾粉的方法
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
NZ735362A (en) 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2619686C2 (de) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
CH670763A5 (OSRAM) * 1985-08-02 1989-07-14 Seuref Ag

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pschyrembel, Klinisches Wörterbuch, 255. Aufl., S. 155 u. 1093 *

Also Published As

Publication number Publication date
CA2056421A1 (en) 1990-12-03
US5266564A (en) 1993-11-30
JP2977894B2 (ja) 1999-11-15
DE3918082C2 (OSRAM) 1992-02-06
JPH04507096A (ja) 1992-12-10
CS276439B6 (en) 1992-05-13
DE59002863D1 (de) 1993-10-28
WO1990014829A1 (de) 1990-12-13
IE901987L (en) 1990-12-02
ATE94757T1 (de) 1993-10-15
EP0474712A1 (de) 1992-03-18
GR900100406A (en) 1991-11-15
AU5670690A (en) 1991-01-07
ZA904196B (en) 1991-03-27
GR1001195B (el) 1993-06-07
ES2060173T3 (es) 1994-11-16
CA2056421C (en) 2000-10-10
IE64039B1 (en) 1995-06-28
DK0474712T3 (da) 1993-11-29
CS268990A3 (en) 1992-01-15
EP0474712B1 (de) 1993-09-22

Similar Documents

Publication Publication Date Title
DE3918082A1 (de) Mittel gegen autoimmunerkrankungen
DE69328474T2 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
DE69434097T2 (de) Apoptose induzierender monoklonaler antikörper
DE69032206T2 (de) Lipid-a-derivate sowie deren verwendungen
DE69125185T2 (de) Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation
DE3534440A1 (de) Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
EP0248062A1 (de) Arzeimittel.
EP1131422A1 (de) Rekombinante glycoproteine, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung
EP0453898A2 (de) Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen
DD241271A5 (de) Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
EP0358130B1 (de) Mittel mit immunsuppressiver Wirkung
DE69617396T2 (de) T-Zellen beeinflussende Peptide
EP0236390B1 (de) Mittel gegen multiple sklerose
DE69116321T2 (de) Immunostimulierendes Mittel das Interleukin-2 und 5'-Deoxy-5-fluorouridin enthält
DE3916417C2 (OSRAM)
DE2048375A1 (de) Wirksammachung von Antibiotika
DE69307895T2 (de) Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin
DE69023559T2 (de) Derivate von Muramyldipeptid.
DE2723451A1 (de) Polyribonucleotide, verfahren zu ihrer herstellung und ihre verwendung als oder in arzneimitteln
DE69233122T2 (de) Verfahren zur Herstellung von Hybridomen
DE2009342A1 (de) Verwendung von Glycerin alkylather (1) phosphorsaure (3) monochohnestern (Äther Lysolecithine) als Mittel zur Stei gerung der natürlichen Resistenz des Or ganismus
DE2546001A1 (de) Immunostimulierende phospholipide und sie enthaltende arzneimittel
DE3883696T2 (de) Anti-Krebs-Mittel und Reagenz zur Gewinnung von Revertanten.
DE2445679B2 (de) Stimulierung der Immunität

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee